Azacitidine, a DNA methyltransferase (DNMT), is the first FDA-approved epigenetically related drug for cancer treatment and is mainly used to treat myelodysplastic syndrome (MDS) [21]. Here, DNMT1 is linked to myelodysplastic syndrome.